Abstract
Introduction
indispensable for viral replication and dissemination, might be another target of protective 81 antibodies. It is known that nonneutralizing antibodies against influenza A virus neuraminidase,
82
which mediates the release of progeny viruses from host cells, play a role in protective immunity 83 (12, 26, 48) . It has also been demonstrated in vitro that the particle release of some viruses (e.g., 84 bovine leukemia, vaccinia, sendai, and rubella viruses) from infected cells was reduced in the 85 presence of MAbs or antiserum (1, 2, 28, 45).
86
In this study, we found that murine MAbs AGP127-8 and MGP72-17 remarkably reduced 87 extracellular release of MARV from infected cells, whereas these antibodies did not inhibit 
110
The media were supplemented with fetal calf serum and antibiotics. fractions. Supernatants and cell lysates were subjected to SDS-PAGE and western blotting. for 60 minutes at 37ºC. Next, the mixture was removed from the cells and 0.5 ml of a 1.2% 162 carboxymethyl cellulose/MEM (Life Technologies) solution was added to each well. Following 163 incubation for 4 days at 37ºC, the plates were fixed with 10% neutral buffered formalin.
164
Subsequently, the cells were permeabilized and foci were stained with anti-MARV NP rabbit serum 165 produced by immunization with a synthetic peptide corresponding to amino acid residues 591-605
166
(GDILEPIRSPSSPSA) of the MARV Angola strain, designated FS0609, followed by an 167 fluorescein isothiocyanate-labeled secondary antibody (Sigma) as described previously (21). Foci 168 were counted using a fluorescent microscope. The neutralization test for pseudotyped VSV was with SDS-PAGE sample buffer with 5% 2-mercaptoethanol and heated for 5 minutes at 98°C.
178
After electrophoresis, separated proteins were blotted on a polyvinylidene difluoride membrane The fixed cells were dehydrated with a series of ethanol gradients, substituted with t-butanol, and and MGP72-17 (IgM) in regard to their inhibitory activities for MARV particle production (Fig. 1) .
234
In the absence of MAbs, NP was detected in the culture supernatants at 48 hpi and the NP and AGP127-8) tested showed neutralizing activity, although the IgM MAbs (AΔM16-2-13 and 250 MGP72-17) minimally neutralized at high concentrations (Fig. 2B) . Similarly, the infectivity of 251 authentic MARV was not reduced by these MAbs in the neutralization test (Fig. 2C) . Importantly, 252 AGP127-8, which almost completely inhibited MARV release from infected cells (Fig. 1) , showed 253 no neutralizing activity. Taken together, these results indicate that the "classical" neutralizing 254 activity of MAbs is not required to inhibit extracellular release of virus particles. comparison to that of intact AGP127-8 IgG (Fig. 3C) . Interestingly, the NP amount detected in the 277 presence of AGP127-8 Fab was comparable to that in the control supernatant (i.e., without MAb) MAbs and examined by confocal microscopy (Fig. 4) . Distribution of GP, VP40, and NP in the We then examined the distribution of AGP127-8 itself in HEK293T cells expressing GP, intracellularly. However, AGP127-8 was only detected on the surfaces of cells expressing GP, 300 VP40, and NP (Fig. S1 ), indicating that AGP127-8 inhibited VLP formation extracellularly. These data suggest that AGP127-8 and MGP72-17 bundle filamentous VLPs on the cell surface 315 during the budding process (Figs. 5E, 5F , 5H, and 5I). protective immunity. In the present study, we propose a novel mechanism by which antibodies 326 counteract MARV particle budding.
327
We found that the budding and extracellular release of MARV were inhibited by MAbs 328 AGP127-8 and MGP72-17 (Fig. 1) , whereas these MAbs did not display "classical" neutralizing 329 activity (Fig. 2) . Morphological analyses by electron microscopy suggested that AGP127-8 and
330
MGP72-17 deposited a tremendous number of unreleased VLPs on the cell surface (Fig. 5) . On the 331 other hand, the AGP127-8 Fab did not inhibit VLP budding (Fig. 3C) , indicating that multiple 332 antigen-binding sites of the intact IgG are a prerequisite for the budding-inhibition activity. Thus, 333 the most plausible explanation for the mechanism underlying the inhibitory effects of these 334 GP-specific MAbs on virus particle budding is that the antibodies crosslink multiple GP molecules 335 expressed on the infected cell surface before initiation of the budding process and, consequently, Interestingly, inhibition of MARV budding by AGP127-8 was not simply dependent on its 351 affinity to GP, since AGP127-8 and AGP126-15 showed similar binding capacities to GPs (Fig. S3) 352 whereas a remarkable difference in the budding-inhibition activities was seen between these MAbs.
353
This indicates that the epitopes of these MAbs are likely the critical factor for the inhibitory budding, which leads to reduced production of progeny viruses. It is noted that the epitope of 363 AGP127-8 is located near the furin cleavage site at the C-terminus of GP1 which is likely 364 unexposed on the uncleaved GP molecules (Fig. S4) . Thus, it can be hypothesized that the 365 C-terminus of cleaved GP1 might have some biological functions to facilitate extracellular virus 366 release.
367
The present study proposes a novel mechanism of antibody-mediated inhibition of MARV 
